| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.1 |